Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
T. Rowe Price Associates, Inc. reported its holdings in Kymera Therapeutics Inc. (common stock) on an amended beneficial ownership report. The firm reported beneficial ownership of 7,112,345 shares, representing 8.6% of the common stock as of June 30, 2026. It reported sole voting power over 7,086,948 shares and sole dispositive power over 7,112,345 shares, with no shared voting or dispositive power. T. Rowe Price Associates stated that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denied such beneficial ownership.
Kymera Therapeutics, Inc. has updated institutional ownership details in an amended Schedule 13G. A group of affiliated Atlas Venture funds collectively report 2,847,541 shares of Kymera common stock, representing 3.4% of outstanding shares based on 83,150,618 shares outstanding as of July 31, 2026. The Fund X entities each have shared voting and dispositive power over 2,384,685 shares, while the Opportunity Fund entities each have shared voting and dispositive power over 462,856 shares. None of the reporting entities has sole voting or dispositive power, and they state that they may be deemed a group but expressly disclaim group status under Section 13.
Kymera Therapeutics reported higher collaboration revenue for the quarter ended June 30, 2026, driven by milestone activity in its partnerships. Collaboration revenue reached $65.0 million versus $11.5 million a year earlier, and was $99.4 million for the first half of 2026 versus $33.6 million in 2025. Quarterly operating expenses rose to $140.6 million, mainly from increased R&D spending of $119.5 million, leading to a net loss of $61.2 million (basic and diluted loss per share $0.62), compared with a $76.6 million loss in the prior-year quarter.
Interest income from the company’s investment portfolio contributed $14.4 million in other income in the quarter. As of June 30, 2026, Kymera held $1,505 million in cash, cash equivalents and marketable securities and reported stockholders’ equity of $1,509.3 million. Net cash used in operating activities was $142.9 million for the first half of 2026. Management states this liquidity is expected to fund operations and capital expenditures for at least twelve months, while the company remains a clinical-stage biotech with ongoing losses and a need for substantial future funding.
Kymera Therapeutics reported second-quarter 2026 results, with collaboration revenue of $65.0 million consisting of a $45 million option exercise fee from Gilead and a $20 million milestone from Sanofi. Research and development expenses were $119.5 million and general and administrative expenses were $21.1 million, resulting in a net loss of $61.2 million, or $0.62 per share. Cash, cash equivalents and investments totaled $1.5 billion as of June 30, 2026, and the company expects this cash balance to provide a runway into 2029.
Kymera also outlined rapid progress in its immunology pipeline. Enrollment in the KT‑621 BROADEN2 Phase 2b atopic dermatitis trial was completed nearly six months early, with topline data now expected by year‑end 2026 and Phase 3 trials planned by mid‑2027. The KT‑621 BREADTH Phase 2b asthma trial is ongoing with data expected in late 2027, KT‑579 Phase 1 data are anticipated in the fourth quarter of 2026, and partnered programs KT‑485 with Sanofi and KT‑200 with Gilead advanced into early clinical and IND‑enabling stages.
Rooney Terence reported acquisition or exercise transactions in this Form 4 filing.
Kymera Therapeutics, Inc. reported that Chief Medical Officer Terence Rooney received equity awards consisting of 76,000 stock options to buy common stock at $110.05 per share, expiring July 26, 2036, plus 38,000 restricted stock units. The RSUs vest in four equal annual installments following July 27, 2026, and the options vest 25% on July 27, 2027 with the remainder in 36 equal monthly installments, in each case subject to his continued employment.
Kymera Therapeutics, Inc. filed an initial statement of beneficial ownership on Form 3 for Rooney Terence, who serves as Chief Medical Officer. This establishes him as a reporting officer under SEC rules and references an Exhibit 24 Power of Attorney relating to SEC filing authorizations.
Kymera Therapeutics, Inc. announced a leadership transition in its Chief Medical Officer role. Jared Gollob, M.D., submitted his resignation as CMO on July 27, 2026, citing personal reasons and indicating it was not due to any disagreement with the company’s practices or policies. He will continue serving as an advisor through December 31, 2026.
Effective July 27, 2026, Terence Rooney, M.D., a veteran immunology drug development leader with experience at Johnson & Johnson, Eli Lilly and Roche, becomes CMO and will lead global clinical development strategy for Kymera’s oral immunology portfolio. The company furnished a press release as Exhibit 99.1 describing his background and Dr. Gollob’s eight years of leadership.
Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported an option exercise and related stock sale. He exercised stock options to acquire 50,000 shares of Common Stock at an exercise price of $2.08 per share, then sold 50,000 Common shares at an average price of $119.00 per share.
Following these transactions, he directly owned 666,568 Common shares. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and the options involved were fully vested and exercisable.
Nello Mainolfi files a Form 144 notifying a proposed sale of 50,000 shares via exercise of stock options. The filing states the transaction is an exercise of stock options to be effected on 07/07/2026 for cash. It also discloses a prior sale of 80,000 shares on 07/01/2026 for $9,223,529.00.
Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of stock option exercises and share sales in Kymera Therapeutics, Inc. common stock. On June 30, 2026, he exercised options to acquire 61,378 shares at an exercise price of $5.33 per share and then sold 77,109 shares in open-market transactions. The sales occurred in multiple trades at weighted average prices within ranges from $110.37 to $118.09 per share, as detailed in the price footnotes. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 23, 2026, indicating they were scheduled in advance. Following the transactions, Jacobs directly holds 244,883 shares of Kymera common stock.